Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunocore appoints CMO

This article was originally published in Scrip

Executive Summary

Immunocore, a biotechnology company developing drugs to treat cancer, viral infections and autoimmune disease, has named Christina Coughlin chief medical officer. Dr Coughlin will be responsible for providing medical and regulatory leadership to the preclinical and clinical programs for the company. Most recently, Dr Coughlin was leading two early development program at Novartis in checkpoint inhibition and PI3'kinase inhibition. Prior to this she was international project team leader at Morphotek, a monoclonal antibody company acquired by Eisai in 2007.

You may also be interested in...



First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic

The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.

COVID-19 Vaccine Expectations Are Ambitious Not Impossible

Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D

Shorla Pharma Sees Opportunity In Re-Innovated Oncology Drugs

Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142350

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel